BRAF and neoplasm: In addition, since BRAF inhibitor alone can cause tumor resistance (60, 61), the combination of BRAF inhibitor with inhibitor targeting MEK, a downstream of BRAF, may be a promising treatment regimen that can avoid the development of drug resistance (62).